Biogen Inc. Stock

Equities

BIIB

US09062X1037

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2024-04-23 pm EDT 5-day change 1st Jan Change
193.2 USD -0.48% Intraday chart for Biogen Inc. -1.01% -25.35%
Sales 2024 * 9.46B Sales 2025 * 9.51B Capitalization 28.22B
Net income 2024 * 1.89B Net income 2025 * 2.2B EV / Sales 2024 * 3.27 x
Net Debt 2024 * 2.7B Net Debt 2025 * 289M EV / Sales 2025 * 3 x
P/E ratio 2024 *
14.7 x
P/E ratio 2025 *
12.8 x
Employees 7,570
Yield 2024 *
-
Yield 2025 *
-
Free-Float 85.34%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.13%
1 week-0.80%
Current month-10.22%
1 month-10.66%
3 months-23.08%
6 months-23.60%
Current year-25.19%
More quotes
1 week
189.44
Extreme 189.44
196.78
1 month
189.44
Extreme 189.44
218.26
Current year
189.44
Extreme 189.44
268.30
1 year
189.44
Extreme 189.44
319.76
3 years
187.16
Extreme 187.16
468.55
5 years
187.16
Extreme 187.16
468.55
10 years
187.16
Extreme 187.16
480.18
More quotes
Managers TitleAgeSince
Chief Executive Officer 64 22-11-13
Director of Finance/CFO 60 20-08-14
Chief Operating Officer - 14-12-31
Members of the board TitleAgeSince
Director/Board Member 75 09-12-31
Director/Board Member 70 19-06-18
Chairman 64 10-01-02
More insiders
Date Price Change Volume
24-04-23 193.2 -0.48% 1 437 482
24-04-22 194.1 -0.14% 1,119,536
24-04-19 194.4 +2.03% 1,599,713
24-04-18 190.5 -0.85% 1,512,073
24-04-17 192.2 -1.53% 1,320,707

Delayed Quote Nasdaq, April 23, 2024 at 12:16 pm EDT

More quotes
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows: - sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.; - royalties (17,2%) ; - other (9,1%): primarily revenues from partnership agreements.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
194.1 USD
Average target price
290.8 USD
Spread / Average Target
+49.83%
Consensus